Indeed, treatment with SIRT1 effectively reduced the levels of both atherogenic lipoproteins (LDL-C and VLDL-C) and pro-inflammatory cytokines, a crucial step in the prevention of ASCVD progression. The gene discussed is SIRT1; the disease is atherosclerosis.